Quantcast

Latest Aortic valve Stories

2014-09-29 12:30:22

JENA, Germany, September 29, 2014 /PRNewswire/ -- Occlutech, a leading innovator of products to treat structural heart disease today announced that it has obtained a European CE Mark approval for its dedicated Paravalvular Leak Closure Device, (PLD). The implant is the world's first, specifically designed device indicated for the minimally invasive closure of leaks occurring around artificial aortic and mitral valves. Tor Peters, CEO of the Occlutech Group, commented:...

2014-09-23 16:27:38

Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval MARLBOROUGH, Mass., Sept. 23, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus(TM) Valve System in patients with severe aortic stenosis and who are considered to be at either high or extreme risk for surgical valve replacement. The Lotus Valve System is the first transcatheter aortic...

2014-09-15 16:28:52

No Cases of Moderate or Severe Paravalvular Aortic Regurgitation at One Year MARLBOROUGH, Mass., Sept. 15, 2014 /PRNewswire/ -- New data from the Boston Scientific (NYSE: BSX) clinical trial program of the Lotus(TM) Valve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement. Data from the REPRISE II clinical trial confirmed safety and effectiveness out to one year,...

2014-09-13 12:20:33

Transcatheter Valve Durability Sustained Through Five Years WASHINGTON, Sept. 13, 2014 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced the presentation of five-year clinical outcomes for inoperable patients treated in The PARTNER Trial, the world's only prospective randomized trial for transcatheter aortic valve replacement (TAVR) in patients deemed too sick for open-heart...

2014-09-09 12:29:07

STASIS Clinical Study Begins in Europe NEWTOWN, Pa., Sept. 9, 2014 /PRNewswire/ -- Micro Interventional Devices, Inc. (MID) reports the first successful clinical case using its Permaseal Cardiac Access and Closure technology. This new technology simplifies minimally invasive aortic valve replacement procedures. The patient is the first to be enrolled in the Secure Transapical Access and Closure Study (STASIS) being conducted in Europe. The first STASIS case was performed by Dr....

2014-08-27 16:25:51

AUSTIN, Texas, Aug. 27, 2014 /PRNewswire/ -- On Aug. 26, 2014, physicians at Heart Hospital of Austin became the first in Texas to implant the new Portico(TM) Re-sheathable Transcatheter Aortic Valve System--an innovative, repositionable aortic heart valve and delivery system. Heart Hospital of Austin is part of the PORTICO trial, a nationwide clinical study to examine the effectiveness of the new heart valve. The Portico valve was used during a catheter-based valve replacement...

2014-08-25 16:26:46

LONDON, Aug. 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/703947/Aortic-Valve-Stenosis-Global-Clinical-Trials-Review-H2-2014.htmlAortic Valve Stenosis Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, "Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014" provides data on the Aortic Valve Stenosis clinical trial...

2014-08-14 12:27:46

CoreValve® System Now Available to More U.S. Patients than any Other Transcatheter Aortic Valve MOUNTAIN VIEW, Calif., Aug. 14, 2014 /PRNewswire/ -- El Camino Hospital became one of the first hospitals in California to adopt a new minimally invasive system to treat patients with narrowed, failing aortic heart valves who are considered to be at high risk to undergo surgery. The U.S. Food and Drug Administration (FDA) approved the Medtronic CoreValve(®) System to treat patients with...

2014-08-13 08:29:50

A congenital heart defect brought Andrew Weaver close to death from end-stage biventricular heart failure. The SynCardia Heart kept him alive and helped build physical strength for his heart transplant. TUCSON, Ariz., Aug. 13, 2014 /PRNewswire/ -- Andrew Weaver and his wife, Heather, feared he wouldn't see their daughter, Haley, grow up because he was dying of heart failure. Instead, Andrew gets to cherish family moments that he would have missed, thanks to the SynCardia temporary Total...

2014-07-31 17:32:49

Oxford University Press Data taken from the German Aortic Valve Registry and published in the European Journal of Cardio-Thoracic Surgery A survey, published online in the European Journal of Cardio-Thoracic Surgery, of 13,860 patients who had undergone interventions for aortic valve disease in Germany has revealed that over 80% were in the same or a better state of health one year after the intervention, and was satisfied with the procedural outcome. Aortic stenosis – the...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'